We are live on !
Find out more
Foundry Partners Portfolio holdings
AUM
$1.89B
Turnover
15.38%
1-Year Est. Return
9.84%
This Fund
S&P 500
This Quarter Est. Return
+1.27%
1 Year Est. Return
+9.84%
3 Year Est. Return
+44.42%
5 Year Est. Return
+233.05%
10 Year Est. Return
+297.72%
AUM
$2.42B
AUM Growth
-$119M
(-4.7%)
Cap. Flow
-$116M
Cap. Flow % of AUM
Cap. Flow %
-4.8%
Top 10 Holdings %
Top 10 Hldgs %
11.89%
Holding
424
New
35
Increased
125
Reduced
216
Closed
37
Avg Time Held
2.5
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Altria Group
MO
|
+$22.3M |
| 2 |
AES
AES
|
+$14M |
| 3 |
Synovus
SNV
|
+$13.3M |
| 4 |
Delta Air Lines
DAL
|
+$12.8M |
| 5 |
Albemarle
ALB
|
+$11.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$21.4M |
| 2 |
Cisco
CSCO
|
+$18.9M |
| 3 |
Johnson & Johnson
JNJ
|
+$16.4M |
| 4 |
HP
HPQ
|
+$13.9M |
| 5 |
GSK
GSK
|
+$13.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 25.11% |
| 2 | Industrials | 15.26% |
| 3 | Technology | 9.77% |
| 4 | Healthcare | 8.29% |
| 5 | Consumer Discretionary | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
JPMorgan Chase
JPM
$919B
| $44.7M | 1.84% |
379,599
-25,650
| -6% | -$2.9M |
2014 Q4
19 quarters
|
|
2
Citigroup
C
$205B
| $39.2M | 1.62% |
567,918
-38,175
| -6% | -$2.6M |
2013 Q4
23 quarters
|
|
3
AT&T
T
$149B
| $33.3M | 1.37% |
1,165,517
-270,838
| -19% | -$7.18M |
2015 Q1
18 quarters
|
|
4
Pfizer
PFE
$165B
| $32.8M | 1.35% |
961,514
+255,796
| +36% | +$9.3M |
2017 Q4
7 quarters
|
|
5
Verizon
VZ
$192B
| $27.2M | 1.12% |
451,250
-30,200
| -6% | -$1.74M |
2017 Q4
7 quarters
|
|
6
DELISTED
LXP Industrial Trust
LXP
| $23.1M | 0.95% |
450,614
+50,864
| +13% | +$2.54M |
2013 Q4
23 quarters
|
|
7
Philip Morris
PM
$310B
| $22.8M | 0.94% |
299,960
-20,150
| -6% | -$1.6M |
2018 Q2
5 quarters
|
|
8
BP
BP
$118B
| $22M | 0.91% |
578,770
-49,565
| -8% | -$1.89M |
2013 Q4
23 quarters
|
|
9
CVS Health
CVS
$114B
| $21.7M | 0.89% |
343,721
+65,940
| +24% | +$3.91M |
2013 Q4
23 quarters
|
|
|
RDS.B
10
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $21.5M | 0.89% |
359,705
-23,825
| -6% | -$1.42M |
2018 Q2
5 quarters
|
|
11
Exelon
EXC
$47.9B
| $21.2M | 0.88% |
616,239
-259,370
| -30% | -$8.71M |
2015 Q1
18 quarters
|
|
12
Old National Bancorp
ONB
$9.48B
| $21M | 0.87% |
1,222,193
-313,622
| -20% | -$5.35M |
2013 Q4
23 quarters
|
|
13
KBR
KBR
$4.49B
| $20.7M | 0.85% |
844,579
+89,291
| +12% | +$2.27M |
2018 Q1
6 quarters
|
|
14
Portland General Electric
POR
$5.47B
| $20.6M | 0.85% |
365,385
+10,327
| +3% | +$575K |
2013 Q4
23 quarters
|
|
15
Tyson Foods
TSN
$20.7B
| $20.5M | 0.85% |
238,290
-15,996
| -6% | -$1.36M |
2013 Q4
23 quarters
|
|
16
Citizens Financial Group
CFG
$27.4B
| $20.5M | 0.84% |
578,450
-38,575
| -6% | -$1.35M |
2016 Q3
12 quarters
|
|
|
17
Johnson & Johnson
JNJ
$688B
| $20.4M | 0.84% |
157,598
-124,710
| -44% | -$16.4M |
2016 Q3
12 quarters
|
|
18
Emcor
EME
$28.9B
| $20.2M | 0.83% |
234,867
-10,765
| -4% | -$916K |
2015 Q3
16 quarters
|
|
19
UFP Industries
UFPI
$4.34B
| $20.2M | 0.83% |
506,368
+24,390
| +5% | +$949K |
2016 Q2
13 quarters
|
|
|
20
Altria Group
MO
$131B
| $19.8M | 0.82% |
+484,800
| New | +$22.3M |
2019 Q3
0 quarters
|
|
21
RTX Corp
RTX
$268B
| $19.8M | 0.82% |
230,786
+56,199
| +32% | +$4.67M |
2016 Q1
14 quarters
|
|
22
Hancock Whitney
HWC
$5.19B
| $19.7M | 0.81% |
514,237
-92,467
| -15% | -$3.52M |
2016 Q2
13 quarters
|
|
23
AllianceBernstein
AB
$3.08B
| $19.4M | 0.8% |
662,472
+54,934
| +9% | +$1.6M |
2017 Q2
9 quarters
|
|
24
PPL Corp
PPL
$26.9B
| $19.1M | 0.79% |
605,396
-40,915
| -6% | -$1.24M |
2014 Q4
19 quarters
|
|
25
Brandywine Realty Trust
BDN
$519M
| $18.4M | 0.76% |
1,217,124
+124,709
| +11% | +$1.82M |
2013 Q4
23 quarters
|
|
Similar funds
PAME
Foundry Partners's Q3 2019 Portfolio in Review
As of Q3 2019, Foundry Partners held 424 positions worth $2.42B, down 4.7% from $2.54B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Foundry Partners withdrew a net $116M in Q3 2019, closing 37 positions and reducing 216 holdings. Its most notable exit was Allergan plc, an estimated $21.4M position sold in full.
By sector, the portfolio is most concentrated in Financials at 25% of assets, down from 25% a quarter earlier, followed by Industrials and Technology.
Against the trend, Foundry Partners opened a new position in Altria Group worth $19.8M.
- Foundry Partners's largest Q3 2019 buy was Altria Group: 484,800 shares worth $19.8M.
- Foundry Partners added most to Gilead Sciences in Q3 2019, an estimated $11.6M increase.
- Foundry Partners's biggest Q3 2019 reduction was Cisco, cutting an estimated $18.9M.
- Foundry Partners fully exited Allergan plc in Q3 2019, selling an estimated $21.4M.
- Foundry Partners's ten largest holdings make up 12% of its $2.42B portfolio in Q3 2019.
- Foundry Partners opened 35 new positions and closed 37 in Q3 2019.
- Foundry Partners's portfolio value fell 4.7% quarter-over-quarter to $2.42B.
Based on Foundry Partners's 13F filing for Q3 2019, filed 23 Oct 2019.